(
(
Healthcare
Healthcare
)
)
NOX inhibitors for unmet conditions - exited
NOX inhibitors for unmet conditions - exited
NOX inhibitors for unmet conditions - exited
STATUS:
Exited
(
(
COMPANY DETAILS
COMPANY DETAILS
)
)
(Entrepreneurs)
(Entrepreneurs)
(VI Partners)
(VI Partners)
(Fund)
(Fund)
Venture Incubator
Portfolio News
DEC 03, 2019
Genkyotex reports progress of Setanaxib Phase 2 investigator initiated trials
Read More
Read more
DEC 03, 2019
Genkyotex reports progress of Setanaxib Phase 2 investigator initiated trials
Read More
Read more
JUL 22, 2019
The WHO recognizes NOX inhibitors as new therapeutic class and approves Setanaxib for GKT831
Read More
Read more
JUL 22, 2019
The WHO recognizes NOX inhibitors as new therapeutic class and approves Setanaxib for GKT831
Read More
Read more
JUN 24, 2019
Final data analysis shows that GKT831 demonstrated statistically significant improvements in GGT and ALP over full treatment period
Read More
Read more
JUN 24, 2019
Final data analysis shows that GKT831 demonstrated statistically significant improvements in GGT and ALP over full treatment period
Read More
Read more